Cecilia J Zhang1, Martin Bidlingmaier2, Mekibib Altaye3, Laura C Page4, David D'Alessio5,1,6, Matthias H Tschöp5,7, Jenny Tong8,1. 1. Division of EndocrinologyMetabolism and Nutrition, Department of Medicine, Duke University, Durham, North Carolina, USA. 2. Medizinische Klinik und Poliklinik IVLudwig-Maximilians-Universität, Munich, Germany. 3. BiostatisticsClinical Translational Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 4. Division of Pediatric Endocrinology and DiabetesDepartment of Pediatrics, Duke University, Durham, North Carolina, USA. 5. Division of EndocrinologyDiabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio, USA. 6. Cincinnati Veterans Affairs Medical CenterCincinnati, Ohio, USA. 7. Institute for Obesity and DiabetesHelmholtz Diabetes Center Munich and Division of Metabolic Diseases, Technical University, Munich, Germany. 8. Division of EndocrinologyDiabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio, USA jenny.tong@duke.edu.
Abstract
OBJECTIVE: To compare the effects of acyl ghrelin (AG) and desacyl ghrelin (DAG) on blood pressure (BP), heart rate (HR) and other autonomic parameters in healthy humans and to elucidate the hormonal mechanisms through which AG could exert its cardiovascular effects. DESIGN: Seventeen healthy participants underwent frequent monitoring of systolic (sBP) and diastolic blood pressure (dBP), HR, respiratory rate (RR) and body surface temperature (Temp) during continuous infusion of AG, DAG, combined AG + DAG or saline control before and during an IV glucose tolerance test on 4 separate days. Plasma catecholamines, renin and aldosterone levels were also measured. Differences in outcome measures between treatment groups were assessed using mixed-model analysis. RESULTS: Compared to the saline control, AG and combined AG + DAG infusions decreased sBP, dBP, mean arterial blood pressure (MAP), HR and Temp. In contrast, DAG infusion did not alter BP, RR or Temp, but did decrease HR. The AG and AG + DAG infusions also raised plasma aldosterone levels compared to saline (P < 0.001) without affecting renin or catecholamine levels. CONCLUSIONS: The decrease in BP, HR, RR and Temp with AG infusion suggests mediation through the autonomic nervous system. The lack of response to DAG suggests that these autonomic effects require activation of the ghrelin receptor.
OBJECTIVE: To compare the effects of acyl ghrelin (AG) and desacyl ghrelin (DAG) on blood pressure (BP), heart rate (HR) and other autonomic parameters in healthy humans and to elucidate the hormonal mechanisms through which AG could exert its cardiovascular effects. DESIGN: Seventeen healthy participants underwent frequent monitoring of systolic (sBP) and diastolic blood pressure (dBP), HR, respiratory rate (RR) and body surface temperature (Temp) during continuous infusion of AG, DAG, combined AG + DAG or saline control before and during an IV glucose tolerance test on 4 separate days. Plasma catecholamines, renin and aldosterone levels were also measured. Differences in outcome measures between treatment groups were assessed using mixed-model analysis. RESULTS: Compared to the saline control, AG and combined AG + DAG infusions decreased sBP, dBP, mean arterial blood pressure (MAP), HR and Temp. In contrast, DAG infusion did not alter BP, RR or Temp, but did decrease HR. The AG and AG + DAG infusions also raised plasma aldosterone levels compared to saline (P < 0.001) without affecting renin or catecholamine levels. CONCLUSIONS: The decrease in BP, HR, RR and Temp with AG infusion suggests mediation through the autonomic nervous system. The lack of response to DAG suggests that these autonomic effects require activation of the ghrelin receptor.
Authors: N Nagaya; M Kojima; M Uematsu; M Yamagishi; H Hosoda; H Oya; Y Hayashi; K Kangawa Journal: Am J Physiol Regul Integr Comp Physiol Date: 2001-05 Impact factor: 3.619
Authors: Alexander F Krapalis; Jacqueline Reiter; Felix Machleidt; K Alexander Iwen; Christoph Dodt; Hendrik Lehnert; Friedhelm Sayk Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-04-04 Impact factor: 3.619
Authors: Andrea Porzionato; Veronica Macchi; Marcin Rucinski; Ludwik K Malendowicz; Raffaele De Caro Journal: Int Rev Cell Mol Biol Date: 2010-03-18 Impact factor: 6.813
Authors: Jianhua Liu; Catherine E Prudom; Ralf Nass; Suzan S Pezzoli; Mary C Oliveri; Michael L Johnson; Paula Veldhuis; David A Gordon; Andrew D Howard; Derrick R Witcher; H Mario Geysen; Bruce D Gaylinn; Michael O Thorner Journal: J Clin Endocrinol Metab Date: 2008-03-18 Impact factor: 5.958
Authors: Kristina M Utzschneider; Jenny Tong; Brenda Montgomery; Jayalakshmi Udayasankar; Fernando Gerchman; Santica M Marcovina; Catherine E Watson; Monica A Ligueros-Saylan; James E Foley; Jens J Holst; Carolyn F Deacon; Steven E Kahn Journal: Diabetes Care Date: 2007-10-01 Impact factor: 19.112
Authors: F Strasser; T A Lutz; M T Maeder; B Thuerlimann; D Bueche; M Tschöp; K Kaufmann; B Holst; M Brändle; R von Moos; R Demmer; T Cerny Journal: Br J Cancer Date: 2008-01-08 Impact factor: 7.640
Authors: Carolina L Haass-Koffler; Victoria M Long; Mehdi Farokhnia; Molly Magill; George A Kenna; Robert M Swift; Lorenzo Leggio Journal: Neuropharmacology Date: 2019-07-13 Impact factor: 5.250
Authors: Mehdi Farokhnia; Kelly M Abshire; Aaron Hammer; Sara L Deschaine; Anitha Saravanakumar; Enoch Cobbina; Zhi-Bing You; Carolina L Haass-Koffler; Mary R Lee; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Int J Neuropsychopharmacol Date: 2021-07-14 Impact factor: 5.176
Authors: Angus P Yu; Felix N Ugwu; Bjorn T Tam; Paul H Lee; Christopher W Lai; Cesar S C Wong; Parco M Siu Journal: Front Endocrinol (Lausanne) Date: 2018-09-12 Impact factor: 5.555
Authors: Xiaolong Wang; Yiming Wang; Christian Gratzke; Christian Sterr; Qingfeng Yu; Bingsheng Li; Frank Strittmatter; Annika Herlemann; Alexander Tamalunas; Beata Rutz; Anna Ciotkowska; Raphaela Waidelich; Chunxiao Liu; Christian G Stief; Martin Hennenberg Journal: Oxid Med Cell Longev Date: 2019-11-22 Impact factor: 6.543